Search

everythinglearnresearchcommunity

for

Search:↓

Intramuscular corticosteroids are effective and safe for severe alopecia areata, with most patients regrowing hair, but nearly half may relapse.

New tools help assess eyebrow, eyelash, and nail changes in Alopecia Areata, improving understanding of patient experiences.

Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.

Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.

Current treatments for alopecia show no significant long-term benefits.

Betamethasone valerate foam is more effective and safe for treating mild-to-moderate alopecia areata than betamethasone dipropionate lotion.

Different treatments for alopecia areata have varying success rates and side effects; intralesional steroids are most effective.

Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.

Most people with Alopecia Areata don't get treatment within a year; it's costly and often comes with other health issues.

Minoxidil effectively and safely treats patchy hair loss, but more research needed.

Non-immune factors play a significant role in alopecia areata.

Mechlorethamine treatment regrew hair in mice by killing immune cells causing hair loss without harming hair follicles.

People with alopecia areata have similar overall death rates as others but higher risks of death from self-harm, psychiatric issues, and lung cancer in certain cases.

Superficial cryotherapy is effective and safe for treating alopecia areata, with better results when used early and frequently.

Liquid nitrogen cryotherapy and betamethasone lotion are equally effective for treating alopecia areata.

PRP did not significantly regrow hair in alopecia areata totalis patients.

Cyclosporine combined with corticosteroids is more effective for severe alopecia areata than cyclosporine alone.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Rare changes in the KRT82 gene are linked to a higher risk of Alopecia Areata.

Nonsteroid treatments for alopecia areata show promise but need more high-quality research.

Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.

Alopecia areata in US adolescents leads to significant healthcare costs and usage.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

The criteria help doctors diagnose and treat alopecia areata more effectively.

Current treatments for severe alopecia areata are unsatisfactory, highlighting the need for better options.

The new hair follicle harvesting technique improves hair transplant results and makes the procedure quicker and easier to learn.